NCT00002368

Brief Summary

To evaluate the tolerance, safety, and effectiveness of Viramune in preventing clinical AIDS progression events or death when used in combination with Lamivudine and background nucleoside therapy.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for phase_3 hiv-infections

Geographic Reach
1 country

53 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 1999

Completed
1.8 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

June 24, 2005

Status Verified

August 1, 2002

First QC Date

November 2, 1999

Last Update Submit

June 23, 2005

Conditions

Keywords

Drug Therapy, CombinationAcquired Immunodeficiency SyndromeNevirapineLamivudineDisease ProgressionReverse Transcriptase InhibitorsAnti-HIV Agents

Interventions

Eligibility Criteria

Age13 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients must have:
  • Documented HIV infection.
  • CD4+ cell count \<= 200 cells/mm3.
  • Life expectancy \> 3 months.
  • Written informed consent from parent or guardian for patients \< 18 years of age.
  • Willingness and ability to follow protocol requirements.

You may not qualify if:

  • Co-existing Condition:
  • Patients with any of the following conditions or symptoms are excluded:
  • Patient is enrolled or plans to enroll during the course of this study in another clinical study of an antiretroviral or other agent used to treat HIV-1 infection.
  • NOTE:
  • Patients are allowed to participate in opportunistic infection clinical studies if the investigational agent is not contraindicated for the study.
  • Concurrent Medication:
  • Excluded:
  • Patient is receiving therapy with an antiretroviral agent other than ZDV, d4T, ddI, ddC, or 3TC.
  • Patient is receiving acute therapy for a clinical AIDS progression event such as systemic chemotherapy.
  • Dicumarol, Warfarin and other anticoagulant medications.
  • Tolbutamide.
  • Investigational drugs (unless included in opportunistic infection clinical trial) and all antiretroviral agents (excluding ZDV, ddC, ddI, d4T and 3TC).
  • Neurotoxic drugs.
  • Cimetidine.
  • Erythromycin.
  • +17 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (53)

Drug Research and Analysis Corp

Montgomery, Alabama, 36104, United States

Location

Dr G Michael Wool

Los Angeles, California, 90067, United States

Location

UCLA School of Medicine / Ctr for Research and Education

Los Angeles, California, 900951793, United States

Location

AIDS Research Ctr / Palo Alto VA Health Care System

Palo Alto, California, 94304, United States

Location

AIDS Community Research Consortium

Redwood City, California, 94063, United States

Location

ViRx Inc

San Francisco, California, 94109, United States

Location

San Francisco Gen Hosp / UCSF AIDS Program

San Francisco, California, 94110, United States

Location

Harbor - UCLA Med Ctr

Torrance, California, 90502, United States

Location

Infectious Disease Specialists

Colorado Springs, Colorado, 80903, United States

Location

Denver Public Health

Denver, Colorado, 80204, United States

Location

Dr Miguel Mogyoros / Clinical Research Dept

Denver, Colorado, 80205, United States

Location

Wilmington Hosp

Wilmington, Delaware, 19801, United States

Location

Novum Inc

Washington D.C., District of Columbia, 20037, United States

Location

Anthony LaMarca

Fort Lauderdale, Florida, 33308, United States

Location

North Broward Hosp District

Fort Lauderdale, Florida, 33316, United States

Location

Dr Robert Schwartz

Fort Myers, Florida, 33901, United States

Location

McGregor Clinic / Lee County Public Health Unit

Fort Myers, Florida, 33901, United States

Location

P Andrew Coley

Jacksonville, Florida, 32216, United States

Location

Goodgame Med Group

Maitland, Florida, 32751, United States

Location

Infectious Disease Research Institute Inc

Tampa, Florida, 33614, United States

Location

Palm Beach Research Ctr

West Palm Beach, Florida, 33409, United States

Location

Dr John Pottage

Chicago, Illinois, 60610, United States

Location

Northwestern Univ / Division of Infectious Diseases

Chicago, Illinois, 60611, United States

Location

Rush Presbyterian / Saint Luke's Med Ctr / Infect Dis

Chicago, Illinois, 60612, United States

Location

Indiana Univ Med School

Indianapolis, Indiana, 46202, United States

Location

Dr Daniel H Gervich

Des Moines, Iowa, 50325, United States

Location

Univ of Iowa

Iowa City, Iowa, 52242, United States

Location

Univ of Kentucky Med Cntr / Dept of Med / Div of ID

Lexington, Kentucky, 40563, United States

Location

Med Research Ctr

New Orleans, Louisiana, 70112, United States

Location

New England Med Ctr

Boston, Massachusetts, 02111, United States

Location

Beth Israel Hosp / Virology Research Clinic

Boston, Massachusetts, 02215, United States

Location

New England Deaconess Hosp

Boston, Massachusetts, 02215, United States

Location

International Medicine and Infectious Disease

Minneapolis, Minnesota, 55407, United States

Location

Trinity Lutheran Hosp / HIV Program

Kansas City, Missouri, 64108, United States

Location

Infectious Disease Associates of Central New Jersey

Somerville, New Jersey, 08876, United States

Location

SUNY / Erie County Med Ctr at Buffalo

Buffalo, New York, 14215, United States

Location

Dr David Kaufman

New York, New York, 10014, United States

Location

Saint Vincent Med Ctr

Staten Island, New York, 10310, United States

Location

Associates in Med and Mental Health

Tulsa, Oklahoma, 74114, United States

Location

The Research and Education Group

Portland, Oregon, 97210, United States

Location

Hershey Med Ctr / Dept of Med / Div of Hematology

Hershey, Pennsylvania, 17033, United States

Location

Univ of Pennsylvania / Division of Infectious Diseases

Philadelphia, Pennsylvania, 19104, United States

Location

Novum Inc

Pittsburgh, Pennsylvania, 152063817, United States

Location

Omega Med Research

Providence, Rhode Island, 02907, United States

Location

Med Univ of South Carolina / Div of Infect Dis

Charleston, South Carolina, 29425, United States

Location

Dr Alfred Burnside

Columbia, South Carolina, 29206, United States

Location

Dr Susie Sargent

Memphis, Tennessee, 38163, United States

Location

Nelson Tebedo Health Resource Ctr

Dallas, Texas, 75219, United States

Location

Univ of Texas Med Branch / Div of Infectious Dis

Galveston, Texas, 775550835, United States

Location

Houston Clinical Research Network / Div of Montrose Clinic

Houston, Texas, 77006, United States

Location

Walter Gaman

Irving, Texas, 75038, United States

Location

Hampton Roads Med Specialists

Hampton, Virginia, 23666, United States

Location

Advanced Research Management

Seattle, Washington, 981225314, United States

Location

MeSH Terms

Conditions

HIV InfectionsAcquired Immunodeficiency SyndromeDisease Progression

Interventions

NevirapineLamivudine

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesSlow Virus DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsZalcitabineDeoxycytidineCytidinePyrimidine NucleosidesPyrimidinesDeoxyribonucleosidesNucleosidesNucleic Acids, Nucleotides, and NucleosidesDideoxynucleosides

Study Design

Study Type
interventional
Phase
phase 3
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 2, 1999

First Posted

August 31, 2001

Last Updated

June 24, 2005

Record last verified: 2002-08

Locations